San Francisco, California, March 16, 2018: TMR Research discusses the future of the U.S. clinical oncology next generation sequencing (NGS) market in latest research report. The research report, titled “U.S. Clinical Oncology Next Generation Sequencing (NGS) Market – Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 – 2024”, provides a detailed review. The study emphatically states that the soaring rise of cancer diagnostics is the very reason for the mushrooming clinical oncology NGS market. Development and introduction of this technology has radically changed the way cancer is understood, treated, and managed amongst patients and medical practitioners.
The growing demand for improved ways of clinical study of cancer has been the driving force behind usage of this technology for cancer molecular diagnosis, prenatal diagnosis, medical genetics and pharmacogenomics, molecular diagnosis of genetic and infectious diseases, carrier detection, and prognosis. The report points out that technologies such as targeted sequencing and re-sequencing will remain key contributors to the swelling revenue of the U.S. clinical oncology next generation sequencing market in the forthcoming years.
Get Sample Copy of this Report @
The report predicts that the market will be buoyed by incredible number of initiatives being taken by the government to offer better healthcare facilities. Furthermore, growing number of investments in research and development of oncology are expected to boost the U.S. clinical oncology next generation sequencing market. However, huge time investment required for research and development of technologies and actually bringing them to the market is a major challenge for the overall market.
Some of the leading players operating in the U.S. clinical oncology next generation sequencing market are Roche, Pacific Bioscience, llumina Inc., GATC Biotech Ag, Macrogen Inc., Agilent Technologies, and Oxford Nanopore Technologies Ltd.